This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Jazz Pharmaceuticals
Information provided by (Responsible Party):
Jazz Pharmaceuticals Identifier:
First received: January 23, 2017
Last updated: August 31, 2017
Last verified: April 2017
This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.

Condition Intervention Phase
Excessive Sleepiness Parkinson Disease Drug: JZP-110 Other: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness

Resource links provided by NLM:

Further study details as provided by Jazz Pharmaceuticals:

Primary Outcome Measures:
  • Safety as assessed by the incidence of treatment emergent adverse events up until the last visit at week 5 [ Time Frame: Weekly through week 5 ]

Secondary Outcome Measures:
  • Assess the effect of JZP110 on the Maintenance of Wakefulness Test (MWT) compared to baseline vs. placebo [ Time Frame: Weekly through week 4 ]
  • Assess the effect of JZP110 on the Epworth Sleepiness Scale (ESS) score compared to baseline vs. placebo [ Time Frame: Weekly through week 4] ]

Estimated Enrollment: 49
Study Start Date: January 2017
Estimated Study Completion Date: April 2018
Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
JZP-110 and Placebo
Drug: JZP-110
75 mg, 150 mg, 300 mg
Other: Placebo
Experimental: Arm B
JZP-110 and Placebo
Drug: JZP-110
75 mg, 150 mg, 300 mg
Other: Placebo
Placebo Comparator: Arm C
Other: Placebo


Ages Eligible for Study:   35 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of idiopathic PD according to the UK PDS Brain Bank Criteria.
  2. Hoehn and Yahr stage 1, 2, or 3.
  3. Baseline ESS score >10.
  4. Baseline mean sleep latency of ≤20 minutes on the MWT.

Exclusion Criteria:

  1. Diagnosis of other degenerative Parkinsonian syndromes (e.g., progressive supranuclear palsy, multiple system atrophy [MSA], or dementia with Lewy bodies [DLB]).
  2. Usual nightly time in bed of <6 hours, including the night before the Baseline visit.
  3. Prior or documented history of moderate or severe obstructive sleep apnea (OSA).
  4. Has evidence at screening of severe cognitive impairment or has cognitive impairment that in the opinion of the investigator would prevent completion of study procedures or the ability to provide informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT03037203

Contact: Jazz Pharmaceuticals 650-496-3777

United States, California
Southern California Institute For Respiratory Diseases, Inc. Recruiting
Los Angeles, California, United States, 90048
Principal Investigator: Roy Artal         
Pacific Research Network, Inc Recruiting
San Diego, California, United States, 92103
Principal Investigator: Stephen Thein         
United States, Florida
QPS MRA (Miami Research Associates) Recruiting
Miami, Florida, United States, 33143
Principal Investigator: Timothy Grant         
QPS MRA (Broward Research Group) Recruiting
Pembroke Pines, Florida, United States, 33024
Principal Investigator: David Seiden         
USF Health Byrd Institute Recruiting
Tampa, Florida, United States, 33613
Principal Investigator: Robert Hauser         
United States, Georgia
NeuroTrials Research, Inc. Recruiting
Atlanta, Georgia, United States, 30342
Principal Investigator: Russell Rosenberg, MD         
United States, Maryland
Center for Sleep & Wake Disorders Recruiting
Chevy Chase, Maryland, United States, 20815
Principal Investigator: Helene Emsellem         
United States, Michigan
Clinical Neurophysiology Services, P.C. Recruiting
Sterling Heights, Michigan, United States, 48314
Principal Investigator: Rahul Sangal         
United States, Missouri
St. Lukes Hospital Medical Center Recruiting
Chesterfield, Missouri, United States, 63017
Principal Investigator: Paula Schweitzer         
United States, New York
Strong Sleep Disorders Center Recruiting
Rochester, New York, United States, 14618
Principal Investigator: Michael Yurcheshen         
United States, Pennsylvania
Parkinson's Disease Research Unit - Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Principal Investigator: Jay Schneider         
United States, South Carolina
SleepMed of South Carolina Recruiting
Columbia, South Carolina, United States, 29201
Principal Investigator: Richard Bogan         
United States, Texas
Houston Neurology and Sleep Center Recruiting
Houston, Texas, United States, 77063
Principal Investigator: Todd Swick         
United States, Washington
Evergreen Hospital Medical Center Recruiting
Kirkland, Washington, United States, 98034
Principal Investigator: Alida Griffith         
Premier Clinical Research - Sherman Active, not recruiting
Spokane, Washington, United States, 99202
Sponsors and Collaborators
Jazz Pharmaceuticals
Study Director: Millie Gottwald, PharmD Jazz Pharmaceuticals
  More Information

Responsible Party: Jazz Pharmaceuticals Identifier: NCT03037203     History of Changes
Other Study ID Numbers: JZP166-201
Study First Received: January 23, 2017
Last Updated: August 31, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Parkinson Disease
Disorders of Excessive Somnolence
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Mental Disorders processed this record on September 21, 2017